Fredag 22 November | 23:54:37 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-11 18:00 Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-06-26 - Årsstämma
2024-04-26 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2024-04-15 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2023-11-30 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-12 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2023-05-11 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2023-02-15 - Extra Bolagsstämma 2022
2022-11-30 - Kvartalsrapport 2022-Q3
2022-08-31 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-12 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2022-05-11 - Årsstämma
2022-02-28 - Bokslutskommuniké 2021
2021-11-30 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-31 - Kvartalsrapport 2021-Q1
2021-04-16 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2021-04-15 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2020-06-30 - Årsstämma
2020-05-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-08 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-06-17 - Årsstämma
2019-04-08 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2019-02-28 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-27 - Kvartalsrapport 2018-Q2
2018-07-25 - Extra Bolagsstämma 2018
2018-05-09 - Kvartalsrapport 2018-Q1
2018-04-19 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2018-04-18 - Årsstämma
2018-02-16 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-10 - Kvartalsrapport 2017-Q2
2017-06-29 - Årsstämma
2017-05-15 - Kvartalsrapport 2017-Q1
2017-04-24 - Extra Bolagsstämma 2017
2017-04-12 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2017-02-14 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-10 - Kvartalsrapport 2016-Q1
2016-04-14 - Årsstämma
2016-03-27 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2016-01-28 - Bokslutskommuniké 2015
2015-10-22 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2015-04-28 - Kvartalsrapport 2015-Q1
2015-03-27 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2015-03-26 - Årsstämma
2015-01-27 - Bokslutskommuniké 2014
2014-10-20 - Kvartalsrapport 2014-Q3
2014-08-19 - Kvartalsrapport 2014-Q2
2014-06-26 - X-dag ordinarie utdelning BRAIN 0.00 SEK
2014-06-25 - Årsstämma
2014-04-14 - Extra Bolagsstämma 2014

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
BrainCool är verksamt inom medicinteknik. Bolaget utvecklar produkter som används inom medicinsk kylning av hjärnan. Teknologin är utvecklad som kylkuddar som appliceras på olika delar av patientens kropp, där systemet kontrollerar kroppstemperaturen. Produkterna används vid behandling av olika allvarliga tillstånd innefattande stroke, hjärtstopp, samt hjärnskakning och migrän. BrainCool grundades 2010 och har sitt huvudkontor i Lund.
2024-04-29 17:40:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

BrainCool AB (publ) (”BrainCool” or the ”Company”) has, in connection with the Company’s upcoming rights issue of shares, that was announced on 15 April 2024 (the “Rights Issue”), prepared an EU Growth Prospectus (the “Prospectus”), which today has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).

Publication of the Prospectus
The Prospectus has been prepared in connection with the Rights Issue and has today, 29 April 2024, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus is available on BrainCool’s website (www.braincool.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se).

For further information on the Rights Issue, please refer to the Prospectus.

Timetable for the Rights Issue

29 April 2024Record date for participation in the Rights Issue
2 May 2024 –13 May 2024Trading in subscription rights on Nasdaq First North Growth Market
2 May 2024 –16 May 2024Subscription period
2 May 2024 – 4 June 2024Trading in BTA
21 May 2024Announcement of the outcome of the Rights Issue

 
Advisors
Zonda Partners AB and DNB Markets, a part of DNB Bank ASA, Sweden Branch are acting as Joint Global Coordinators in connection with the Rights Issue. Setterwalls Advokatbyrå AB is acting as legal advisor to the Company and Nordic Issuing AB is acting as issuing agent in connection with the Rights Issue.

For more information, contact
Jon Berg – CEO
+46 722 50 91 19
jon.berg@braincool.se

The information was submitted for publication, through the agency of the contact person set out above, on 29 April 2024, 17:40 CEST.

About Us
BrainCool AB (publ) is an innovative medical technology company that develops, markets and sells leading medical cooling systems for indications and areas with significant medical added value in healthcare. BrainCool AB (publ) is headquartered in Lund, Sweden. The share is listed on Nasdaq First North Growth Market, under the ticker “BRAIN”. The Company’s Certified Adviser is Eminova Fondkommission AB.
 
IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in BrainCool. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for shares in BrainCool has only been made through the Prospectus that BrainCool published on 29 April 2024 on BrainCool’s website, www.braincool.se. The approval of the Prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the Company’s shares or any other securities. This release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 (“Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares or other securities in BrainCool. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in BrainCool have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area (“EEA”), no public offering of shares or other securities (“Securities”) is made in other countries than Sweden. In other member states of the European Union (“EU”), such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); (ii) high net worth entities etc. falling within Article 49 (2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company’s current view on future events and financial and operational development. Words such as “intend”, “will”, “expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

This information, the opinions and the forward-looking statements included in this press release are only applicable as of this date and may change without any notice thereof. BrainCool does not undertake to publish any updates or amendments of forward-looking statements, future events or similar circumstances other than what is required by appliable legislation.

As BrainCool conducts activities worthy of protection in accordance with the Act (2023:560) on the Screening of Foreign Direct Investments, certain investments in the Rights Issue may require review by the Swedish Inspectorate of Strategic Products. The Company will, no later than in connection with the publication of the Prospectus, publish more information about this on the Company’s website, www.braincool.se.